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What you need to know
• Most people with peripheral artery disease are asymptomatic
• Peripheral artery disease is associated with a high risk of vascular
complications such as myocardial infarction, stroke, vascular dementia,
renovascular disease, and mesenteric disease
• Few patients with intermittent claudication develop limb-threatening
complications (1-3% in 5 years)
• Management of risk factors—including smoking, diabetes, and
dyslipidaemia—is key to reducing the risk of vascular complications
• Patients with critical limb ischaemia are at high risk of limb amputation
and premature death
Peripheral artery disease affects around 13% of the Western
population who are more than 50 years old.1 It is most commonly
due to atherosclerosis, where an atherosclerotic plaque causes
arterial stenosis or occlusion. This results in a reduction in blood
flow to the affected limb. Most patients are asymptomatic, but
many experience intermittent claudication (pain on walking).
Critical limb ischaemia occurs when the reduction in blood flow
is so severe that it causes pain on rest or tissue loss (ulceration
or gangrene).1
Atherosclerosis is a systemic disease. Some 60% of patients
with peripheral artery disease will have ischaemic heart disease,
and 30% have cerebrovascular disease.2 Within five years of
diagnosis, 10-15% of patients with intermittent claudication
will die from cardiovascular disease.3 Therefore, management
begins with identification and modification of risk factors that
are common to peripheral artery disease, heart disease, and
stroke.
Sources and selection criteria
We used Healthcare Databases Advanced Search (HDAS) to search Embase,
Medline, and PubMed for the most up to date systematic reviews and
meta-analyses or alternative highest level of evidence on peripheral artery
disease or intermittent claudication. Searches were performed during
September 2017 with no date limits applied.
We also consulted national and international guidelines, particularly those
published by the National Institute for Health and Care Excellence (NICE) and
the Trans-Atlantic Inter-Society Consensus for the Management of Peripheral
Artery Disease (TASC II). TASC guidelines are developed by a worldwide
working group and are based on the best evidence available in vascular
surgery.
Relevant citations were also drawn from the content of initially identified papers.
Who is at risk?
The development of peripheral artery disease is multifactorial.
Two large population studies found that over 95% of patients
have at least one cardiovascular risk factor.4 5
Smoking
Results from a systematic review of 17 studies including 20 278
patients suggest that half of all peripheral artery disease can be
attributed to smoking. It concluded that heavier smokers are
more likely to develop peripheral artery disease than light
smokers and that former smokers have a persistently increased
risk compared with never smokers.6
Diabetes
The TASC II guidelines conclude that, for all patients with
diabetes, the relative risk of developing peripheral artery disease
is similar that of people who smoke.3 7 A prospective cohort
study of 1894 diabetic participants found that poor diabetes
control was associated with an increased risk of peripheral artery
disease.8 Patients with diabetes are more likely to be
asymptomatic because of the co-existence of neuropathy in a
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substantial proportion. Peripheral artery disease in this
population is more likely to be found in more distal vessels in
the calf.3 Population studies have found that around half of
patients with a diabetic foot ulcer have peripheral artery
disease.9 10
Other
The prevalence of peripheral artery disease increases with
advancing age; one population study of 2174 participants found
an increase from 1% of 40-49 year olds to 15% of those aged
over 70.4 11 12 The same study found that black ethnicity increased
the risk of peripheral artery disease (odds ratio 2.83, 95%
confidence interval 1.48 to 5.42).4 This difference persists after
correcting for conventional risk factors.4 13-15 TASC II guidelines
conclude that men are affected at a younger age than women,
but overall there is no clear distinction in risk.3 They also
concluded that high fasting serum cholesterol level,
hypertension, and chronic kidney disease each increase in the
risk of peripheral artery disease by 1.5 times. Peripheral artery
disease is also associated with high serum homocysteine.3
What are the long term outcomes?
If left untreated, peripheral artery disease does not inevitably
lead to amputation. A prospective population study showed that
most patients with claudication have stable or improved
symptoms at five years from diagnosis.16 Asymptomatic disease
is a marker of sedentary lifestyle rather than less severe disease
and outcomes are similar to those with claudication. Up to 25%
of symptomatic patients will need intervention, but fewer than
5% will progress to critical limb ischaemia.3 17 Within five years
from diagnosis of peripheral artery disease, the risk of
amputation is 1-3.3% and all-cause mortality is 20%.3
If a patient develops critical limb ischaemia, overall survival is
worse than for many cancers. In patients with critical limb
ischaemia the one-year risk of limb amputation is 30% and
five-year all-cause mortality is 50%.3 A cross sectional study
of 2 730 742 patients with peripheral artery disease found
mortality rates for all patients requiring leg amputation were
twice as high as for those without amputation (P<0.001).18 A
study of 136 patient records found that patients with diabetes
were more likely to require amputation (odds ratio 5.4,
P<0.0001) or die (odds ratio 3.1, P<0.002) compared with those
non-diabetic patients.19
What are the symptoms?
Most patients with peripheral artery disease are asymptomatic.1 20
Claudication is an aching or burning in the muscles of the leg.
It is reliably reproduced at a set distance of walking and is
relieved within minutes on rest. It is never present at rest or
exacerbated by position.
The site of pain provides an indication of the site of disease.
Stenosis or occlusion of the aorta is likely to cause bilateral
buttock, thigh, and calf claudication. Occlusion of the common
iliac, common femoral, and superficial femoral arteries cause
unilateral buttock, thigh, and calf claudication respectively (see
infographic). There are several key differential diagnoses in
anybody presenting with lower limb pain related to exercise
(table 1).
Critical limb ischaemia is often resistant to opiate analgesia and
may be difficult to distinguish from neuropathy. Patients
describe hanging their leg over the edge of the bed to relieve
the pain. Acute limb ischaemia is rare but important not to miss
as delays increase the risk of limb amputation. This classically
presents with sudden onset symptoms and one or more of the
“six Ps” (see infographic and box 1).
Box 1: Symptoms in common vascular presentations
Intermittent claudication
Claudication in calf, thigh, or buttock
Critical limb ischaemia
One or more of:
• Ulceration
• Gangrene
• Rest pain in foot for >2 weeks
Acute limb ischaemia







• Sudden deterioration of claudication
*Not all of the “six Ps” need to be present for diagnosis
What assessments are needed?
When assessing such patients, answering the following three
questions will direct management in primary and secondary
care:
1.Does this patient have peripheral artery disease?
•Symptoms
• Impalpable or reduced pulses
•Reduced ankle-brachial pressure index (ABPI) ≤0.9
2.Is the disease acute or chronic?
•Duration of onset
•Risk factors (such as atrial fibrillation for acute ischaemia,
smoking for peripheral artery disease)
3.What is the severity of disease?
•Claudication
•Critical limb ischaemia
•Acute limb threatening ischaemia
Lack of a palpable pulse is the most sensitive clinical sign.
Examine pulses in the leg working distally from the groin.
Capillary refill and foot characteristics (hair loss, colour) are of
little diagnostic importance.21 22 Look particularly for hidden
tissue loss on the heel or between toes (fig 1). Identification of
peripheral neuropathy with a monofilament is useful in those
at risk (such as people with diabetes) as it often coexists.
An ankle-brachial pressure index (ABPI) test is the ratio of
blood pressure at the ankle to blood pressure at the arm. It should
always be done in cases of suspected peripheral artery disease,
but it has limitations. Although a value of ≤0.9 or less is
diagnostic of peripheral artery disease, falsely elevated (>1.2)
and unreliable values are often seen in patients with diabetes
and renal failure because of arterial calcification. A normal
ABPI in the presence of tissue loss does not exclude critical
limb ischaemia and such a patient would still require urgent
referral (see infographic and box 1).23 Toe brachial index is an
alternative if available (a value <0.7 indicates peripheral artery
disease).
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Other investigations are detailed in box 2. These often reveal
coexisting disease (such as diabetes or abdominal aortic
aneurysm) that requires separate management.
Box 2: History, examinations, and investigations for suspected
peripheral artery disease
History
• Previous manifestations of:






• Palpation of peripheral pulses (including abdominal aortic aneurysm)
• Peripheral neuropathy (if at risk)
Investigations
• Ankle-brachial pressure index (ABPI)
• Blood pressure
• Electrocardiography
• Full blood count
• Urea and electrolytes
• Random blood glucose or HbA1c
• Serum cholesterol
• Thrombophilia screen if patient <50 years old
How can peripheral artery disease be
managed in primary care?
Asymptomatic patients and those with claudication can both be
managed in primary care (box 3). In England, the Quality and
Outcomes Framework (QOF) requires that patients with
peripheral artery disease are established on a register in primary
care.25 Registries also exist in Europe. Documenting the distance
walked until onset of symptoms allows progression of the
disease to be monitored. Intervention is unnecessary if there is
no impairment in quality of life, but risk factor identification
and management must take place. Evidence from large
population studies have found less than half of these patients
have adequate risk factor modification by time of referral.26-28
Box 3: Key aspects of managing peripheral artery disease in
primary care
All patients should receive the following (where applicable) before referral to
secondary care
Risk factor modification
• Smoking cessation therapy
• HbA1c control (target value <48 mmol/mol)
• Blood pressure control (target <140/90 mm Hg*)
• Clopidogrel (or aspirin) 75 mg lifelong
• Atorvastatin 80 mg† lifelong
Symptom control
• Supervised exercise therapy for 3 months
*Target blood pressure is for patients <80 years old. If >80 years, target is
150/90 mm Hg.
†Dose for secondary prevention of cardiovascular disease.24
Risk factor modification
Patients with peripheral artery disease have persistently worse
outcomes if they continue to smoke. Multiple cohort studies
have shown that, compared with former smokers, patients who
still smoke have a higher risk of amputation, and their chance
of surviving five years from diagnosis is halved compared with
non-smokers.29-32 Patients must be informed of this association
and directed to relevant smoking cessation services at all
interactions. Combining behavioural counselling with
medication (varenicline is most effective) increases the
proportion of successful quitting attempts compared with
standard care.33-36 Smoking cessation may prevent a decline in
symptoms.
Antiplatelets reduce the risk of major cardiovascular events. A
randomised control trial (RCT) of 19 185 patients with
atherosclerotic vascular disease showed that clopidogrel 75 mg
was significantly better than aspirin 325 mg for prevention of
vascular complications (P=0.043, 95% CI 0.3 to 16.5) at a mean
follow up of 1.91 years. 23 If clopidogrel is contraindicated,
aspirin remains an acceptable alternative.23 37, 38 A network
meta-analysis of 49 RCTs revealed that, although dual
antiplatelet therapy can reduce the rate of major amputations
(relative risk 0.68, 95% CI 0.46 to 0.99), it causes an
unacceptable increase in risk of severe bleeding (relative risk
1.48, 1.05 to 2.10) compared with aspirin alone, and clopidogrel
has the most favourable benefit-harm profile (79% cumulative
rank probability best and 77% cumulative rank probably
safest).38 Warfarin is usually reserved for those with limb
ischaemia due to arterial emboli.39
A meta-analysis of two RCTs and 12 observational studies
showed that statin therapy reduces all-cause mortality (odds
ratio 0.77, 95% CI 0.68 to 0.86) and the incidence of stroke
(odds ratio 0.77, 0.67 to 0.89) in patients with peripheral artery
disease.40 A cohort study found no effect on limb amputations
(P=0.84).41 Three RCTs have not resolved whether statins affect
walking distance.42-44 NICE recommends reducing non-HDL
cholesterol concentration in patients with peripheral artery
disease by 40%.24
Multiple studies have shown that improved glycaemic control
in patients with diabetes reduces the risk of microvascular
complications, but it seems to have little effect on the risk of
limb amputations.45-47 NICE recommends a target HbA1c level
<48 mmol/mol for all patients with diabetes.48
Hypertension management lowers cardiovascular risk, and
ramipril is recommended as first line therapy in guidelines
worldwide.3 23 49 A systematic review and meta-analysis of four
RCTs did not show that it improved claudication symptoms in
patients with symptomatic peripheral artery disease.50
All patients who are overweight (body mass index >25) should
be given an optimal diet plan and a goal for weight loss.3
Symptom management
Exercise
Several meta-analyses of RCTs have found that supervised
exercise improves walking distance in patients with peripheral
artery disease compared with unsupervised regimens (relative
risk 0.48, 95% CI 0.32 to 0.64, at 6 months).51-53 Improvement
occurs in the absence of improved ABPI.52 The benefit to
walking ability and quality of life is similar whether patients
undergo supervised exercise therapy or angioplasty.54 The most
effective therapy is walking for more than 30 minutes, at least
three times a week, to near maximal pain, for at least six
months.55
NICE recommends a supervised exercise programme is offered
to all patients (2 hours a week for 3 months) if available.23 This
is more cost effective than either unsupervised exercise or
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angioplasty. However, it is estimated that 70% of clinical
commissioning groups in the UK do not provide this service,
which costs £255 per person for three months.56
Vasoactive drugs
Naftidrofuryl oxalate and cilostazol both improve walking
distance in patients with intermittent claudication. 57-59
Naftidrofuryl oxalate is the most cost effective and efficacious
(up to 60% improvement).57,59 NICE recommends it when
supervised exercise does not result in satisfactory improvement
and the patient prefers not to be referred to secondary care. If
there is no benefit after 3-6 months, it should be stopped.23 A
meta-analysis of four RCTs found that angiotensin converting
enzyme (ACE) inhibitors also modestly improved pain-free
walking distances in patients with claudication by 86 m (95%
CI 13 to 156 m, P=0.021).60
When should patients be referred to
vascular surgery?
Urgently refer any patient presenting with critical limb ischaemia
or acute limb ischaemia (box 1) to a vascular centre for specialist
assessment. Urgently refer those with a diabetic foot ulcer and
peripheral artery disease to the diabetic foot multidisciplinary
team (see fig 2).48
Refer patients with claudication that affects their quality of life
and who do not improve after three months of supervised
exercise therapy to a vascular surgeon for consideration of
revascularisation procedures.23 61
What are the treatment options in secondary
care?
Revascularisation
Limb revascularisation is risky and can itself result in
amputation. In cases of claudication, it is recommended only
when there is significant impairment in function and quality of
life.62 This contrasts with critical limb ischaemia, for which
revascularisation is an urgent limb-saving and lifesaving
procedure. Patients referred to vascular surgery will undergo
further imaging with Duplex ultrasound or cross-sectional
imaging (magnetic resonance or computed tomography
angiography).
Where the atherosclerotic lesions are favourable (a small,
singular stenosis or occlusion) an “endovascular first” strategy
is often used.63 This may involve placement of a stent.
Angioplasty is generally avoided below the level of the knee
because of its poor durability in people with claudication. Open
surgery is considered in patients with debilitating symptoms
who are unsuitable for primary angioplasty (multiple or large
occlusions) or in whom angioplasty has failed.20 64
Non-invasive interventions
Non-invasive interventions are ineffective in peripheral artery
disease. Prostanoid infusions (such as iloprost) may be used in
vasospastic conditions (such as Raynaud’s phenomenon), but
they provide only short term improvement in symptoms.65 66
There are few indications for their use in critical limb ischaemia.
Future directions for vascular surgery
Future developments in vascular surgery are aimed at improving
endovascular techniques and technology. Drug eluting
technologies are currently being evaluated in randomised trials
(BASIL-3). The BASIL-2 trial is assessing revascularisation
options in patients with peripheral artery disease below the knee
(typically seen with diabetes).67 Other devices enabling
endovascular removal of atheroma—cryoplasty, laser, and
bio-absorbable vascular scaffolds—are also under
investigation.63
Questions for future research
• Is it possible to prevent critical limb ischaemia?
• What is the optimal medical therapy to reduce cardiovascular risk in
patients with peripheral artery disease?
Additional educational resources
• National Institute for Health and Care Excellence. Peripheral arterial
disease: diagnosis and management (clinical guideline CG147). 2012.
www.nice.org.uk/guidance/cg147
• Gerhard-Herman et al. 2016 AHA/ACC Guideline on the Management
of Patients With Lower Extremity Peripheral Artery Disease: Executive
Summary: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines. Circulation
2017;135:e686-e725.
• Norgren et al. Inter-society consensus for the management of peripheral
arterial disease (TASC II). J Vasc Surg 2007;45:S5-S67.
• Video of peripheral arterial examination. www.youtube.com/watch?
v=5HUJ9iI5QiQ
• Video of measuring ankle-brachial pressure index (ABPI). www.youtube.
com/watch?v=3tU2kU1FkIg
Information resources for patients
• Circulation Foundation vascular charity. www.circulationfoundation.org.
uk
• Treating intermittent claudication. In: National Institute for Health and
Care Excellence. Peripheral arterial disease: diagnosis and management
(clinical guideline CG147). 2012. www.nice.org.uk/guidance/cg147/ifp/
chapter/treating-intermittent-claudication
Education into practice
• What proportion of your patients with peripheral artery disease have
appropriate cardiovascular risk factor modification?
• What proportion of your patients with intermittent claudication are offered
supervised exercise therapy as first line management?
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Table
Table 1| Differential diagnoses of intermittent claudication
DifferentiationCondition
Non-vascular
Relieved by position change, may have leg weaknessSpinal stenosis
Not quickly relieved by restOsteoarthritis
Straight leg raise test is positiveLumbar nerve root irritation
Vascular
History of deep vein thrombosis, pain relief on leg elevation, oedema, venous skin changesVenous claudication
Young male smokersBuerger’s disease (thromboangiitis obliterans)
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Figures
Fig 1 Ischaemic right foot demonstrating discoloration and tissue loss at the tip of the hallux
[Image: DR P. MARAZZI/SCIENCE PHOTO LIBRARY]
Fig 2 Primary care decisions flowchart. For further information about diabetic foot ulcers see NICE guidelines.48 Patients
should also be referred if there is diagnostic uncertainty
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